“An article published today by Bloomberg does not accurately reflect PhRMA’s position on Medicare Part D or other health care policy issues. The article is based on improperly obtained internal documents that were in draft form. The documents do not contain official PhRMA policy positions, which are set by the organization’s Board of Directors.

PhRMA remains committed to its core principles of fostering medical innovation and supporting patient access to new medicines. As Congress debates today’s pressing health care and fiscal issues, PhRMA recognizes that policymakers may consider many options and at this early stage there are numerous open questions. PhRMA looks forward to working with policymakers on bipartisan solutions that are best for patients and support continued medical advances.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.